Highlights Qiagen N.V. Swiss Exchange

Equities

QGEN

NL0015001WM6

Market Closed - Swiss Exchange Other stock markets 09:05:20 28/06/2019 pm IST			5-day change	1st Jan Change
39.45 ^CHF	+0.84%		-.--%	-.--%

31/05	Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	MT
31/05	Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	31/05	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	31/05	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	31/05	CI
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine	30/05	CI
Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	15/05	MT
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	15/05	CI
Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results	13/05	CI
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	08/05	MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	08/05	CI
QIAGEN Announces the Availability of QCI Secondary Analysis	03/05	CI
QIAGEN : A decent start to 2024; guidance unchanged	30/04
Qiagen Seeks Acquisitions	30/04	CI
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours	30/04	MT
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024	30/04	CI
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	25/04	CI
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	04/04	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	27/03	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	26/03	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	19/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 07:02 pm IST